← ANALYSTS · TIPRANKS
Eric Schmidt FCA · Cantor Fitzgerald
Hits
51%
22 of 43 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
+84.1%
Over a year after the rating, TipRanks’ measure
Our companies rated now
9
Buy / hold / sell: 9 / 0 / 0
Upside of the analyst’s targets
+144.5%
Average over 2 current targets, to the last price
The market’s answer to the ratings
−0.6%
Day-0 move against SPY in the rating’s direction, average over 8 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Oct 13on TipRanks 06:35 | ETRAElectra Therapeutics Inc. · $585M | Initiated | Buy | — | — | −7.6%next day +4.9% | ↗ |
| Sep 21on TipRanks 10:40 | FDMTIWM4D Molecular Therapeutics · $711M | Upgrade | Buy | — | — | −1.4%next day +4.2% · 5 days −3.4% | ↗ |
| Jul 23on TipRanks Jul 24 05:10 | DYNIWMDyne Therapeutics · $2.9B | Initiated | Buy | — | — | +4.2%next day +2.2% · 5 days +7.2% | ↗ |
| Jun 22on TipRanks 08:55 | BIIBSPYBiogen · $34.8B | Initiated | Buy | $206 | −11.5% | +1.9%next day +0.2% · 5 days +8.9% | ↗ |
| Jun 2on TipRanks 06:10 | ODTXIWMOdyssey Therapeutics, Inc. · $844M | Initiated | Buy | — | — | −0.3%next day −0.7% · 5 days +3.9% | ↗ |
| Mar 24on TipRanks 06:30 | GENBIWMGenerate Biomedicines, Inc. · $1.6B | Initiated | Buy | — | — | −3.6%next day −2.2% · 5 days +4.3% | ↗ |
| Mar 19on TipRanks Mar 20 06:15 | SRRKIWMScholar Rock Holding · $4.9B | Reiterated | Buy | — | — | +14.6%next day −0.5% · 5 days −0.9% | ↗ |
| Dec 17on TipRanks 08:00 | LEGNLegend Biotech · $3.5B | Reiterated | Buy | $75.00 → $74.00−1.3% | +300.4% | 0.0%next day −1.4% · 5 days +4.2% | ↗ |
| Oct 16on TipRanks 07:35 | VSTMIWMVerastem · $836M | Initiated | Buy | — | — | +1.9%next day −3.6% · 5 days −19.6% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗